$ZNTL

Zentalis Pharmaceuticals Inc

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Miscellaneous
  • Investment Trusts/Mutual Funds
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$29.03 ▲3.31%

Last Close

VOLUME

1,202,579

DAY RANGE

27.55 - 29.25

52 WEEK

17.33 - 87.19

Join Discuss about ZNTL with like-minded investors

profile
@dros #droscrew
recently

+Initiations 1/20: $AYX $BRBR $CAT $CKPT $DDOG $DE $DELL $DEN $DMYD $DT $EL $ELS $ESTC $FICO $GTLS $KDP $KO $MO $PENN $PII $RXN $SNES $SPNS $STLA $TEX $URI $UTZ $ZNTL $ZS . -Initiations 1/20: $CL $LECO $PEP

68 Replies 10 👍 6 🔥

profile
@Benlax #droscrew
recently

+Initiations 8/27: $ARCB $DRI $ESTA $FIS $FISV $GRWG $HZNP $MA $MRVL $NOG $PSNL $PYPL $RCEL $SQ $UPWK $V $WEX $ZNTL

77 Replies 8 👍 12 🔥

Key Metrics

Market Cap

1.35 B

Beta

2.01

Avg. Volume

717.32 K

Shares Outstanding

46.63 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-11

Next Dividend Date

Company Information

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies, and ZN-e4, an EGFR inhibitor for non-small cell lung carcinoma (NSCLC). Zentalis has licensed ZN-c5, ZN-c3 and ZN-d5 to its majority-owned joint venture, Zentera Therapeutics, to develop and commercialize these candidates in China. Zentalis has operations in both New York and San Diego.

Website:

HQ: ,

Related News